Ibogaine for PTSD: What the Research Shows and Who It Helps
PTSD is not a veteran's condition. That framing has dominated public understanding for years — understandably, given the scale of combat trauma and the research focus that followed. But the data on who actually lives with PTSD tells…
What does the research show for ibogaine and PTSD?
The strongest data is the 2024 Stanford study: 30 special-operations veterans saw PTSD symptoms fall 88% on average one month after one magnesium–ibogaine treatment, alongside gains in depression, anxiety and cognition. It was open-label with no control group, and PTSD is not only a veteran's condition — clinics treat civilian trauma the same way.
PTSD is not a veteran’s condition. That framing has dominated public understanding for years — understandably, given the scale of combat trauma and the research focus that followed. But the data on who actually lives with PTSD tells a different story: sexual assault survivors, childhood abuse survivors, people who have been through medical crises, first responders, accident victims, and anyone who has experienced events their nervous system filed as catastrophic.
The Research Record
Ibogaine Research Timeline
Where the evidence actually stands — described as research, not results.
- 1993
The FDA approves a Phase I safety trial led by Dr. Deborah Mash at the University of Miami — the first US-sanctioned human study. Funding lapses before Phase II.
- 2017
A New Zealand observational study follows opioid-dependent patients through legal ibogaine treatment over 12 months. Noller et al., Am J Drug Alcohol Abuse, n=14, observational
- 2024
Stanford’s Magnesium–Ibogaine study (MISTIC) reports on 30 US Special Operations veterans with traumatic brain injury treated in Mexico — an open-label study, not a controlled trial. Cherian et al., Nature Medicine 2024, n=30, open-label
- 2025–26
Texas funds ibogaine research — state legislation directs public money toward FDA-pathway clinical trials, the largest US public investment in the compound to date.
All entries describe published research and public records. Open-label and observational designs cannot establish efficacy; controlled trials are still ahead.
Related on this site: ibogaine for PTSD · PTSD and trauma · MDMA therapy · ibogaine for veterans · ibogaine safety guide
What do people ask about Ibogaine for PTSD: What the Research Shows and Who It Helps?
Does ibogaine help non-veteran PTSD?
The protocol is the same; the published data is in veterans. Evidence for civilian trauma is observational.
How does it compare with MDMA therapy?
MDMA has phase-3 randomised evidence but limited legal access; ibogaine is a single treatment abroad with open-label evidence.
Who is not a candidate?
People with certain cardiac conditions or medications that cannot be tapered; screening decides.
Sources and further reading
- Nature Medicine (2024): magnesium–ibogaine therapy in veterans with traumatic brain injury — open-label, n=30, no control group
- Nature Medicine (2021): MDMA-assisted therapy for severe PTSD, phase 3 — randomised, n=90
Speak with an advisor.
A confidential conversation about your situation and the options actually worth considering — from people who visit every provider they recommend.